Results of seton drainage and infliximab infusion for complex anal Crohn's disease

Hepatogastroenterology. 2011 Jul-Aug;58(109):1189-92. doi: 10.5754/hge09586.


Background/aims: To investigate the efficacy of infliximab for complicated perianal Crohn's disease with special reference to maintenance therapy.

Methodology: Between June 2002 and April 2009, 20 patients (15 men and 5 women, aged 31.4±2.9 years old (mean ± standard error)) with complicated fistulizing anal Crohn's disease underwent seton placement. For the induction therapy, intravenous infusion of infliximab was given 3 times after surgical treatment. Thereafter, infliximab was given every 8 weeks as maintenance therapy. Patients were followed-up for 31.8±4.2 months after the first infliximab infusion. The number of the infliximab treatments given was 13.6±2.5.

Results: After induction therapy, complete response (CR) was observed in 8 patients (40%), partial response (PR) in 9 and progress disease (PD) in 3. With (n=17) or without (n=3) maintenance therapy following the induction therapy, CR was observed in 15 of 20 patients (75%). Of the 17 patients who received maintenance therapy, CR was of observed in 13 patients, of whom 7 patients showed PR or PD before maintenance therapy.

Conclusions: Seton drainage and infliximab therapy is effective in the patients with fistulizing perianal Crohn's disease. Maintenance infliximab therapy might be effective in patients with perianal Crohn's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Crohn Disease / complications
  • Crohn Disease / therapy*
  • Drainage*
  • Female
  • Humans
  • Infliximab
  • Infusions, Intravenous
  • Male


  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Infliximab